Summary & Overview
Skin Grafts and Wound Debridement for Endocrine, Nutritional and Metabolic Disorders with MCC: Inpatient Reimbursement Overview
DRG 622 encompasses inpatient admissions for skin grafting and wound debridement in the setting of endocrine, nutritional, and metabolic disorders with a Major Complication or Comorbidity. It defines a higher-weighted Diagnosis-Related Group used by Centers for Medicare & Medicaid Services to adjust Medicare inpatient reimbursement for complex surgical and medical resource use.
DRG 622 Overview
DRG 622 covers inpatient admissions involving skin grafts and extensive wound debridement for patients with underlying endocrine, nutritional, and metabolic disorders accompanied by a Major Complication or Comorbidity. Typical cases include diabetic patients or those with metabolic dysregulation requiring surgical wound management and resource-intensive perioperative care. This Diagnosis-Related Group matters for Medicare payment because it groups high-acuity surgical wound care with significant comorbidity burden, affecting reimbursement levels and hospital case-mix considerations.